Tanimoto Sarina

CMO Sarina Tanimoto sold 50,000 shares (50.0K shares) for $703,755.30 across two days at blended average $14.08

Tanimoto executed two separate sales totaling 50,000 shares over two consecutive days (12,344 shares at $14.03 on 2025-08-19 and 37,656 shares at $14.09 on 2025-08-20), reducing her holdings from 1.30M shares to 1.25M shares (-3.9%). At the same ticker, her prior 5 trades show a 5 of 5 well-timed pattern at the 90-day mark, with the most recent sales in December 2024 occurring shortly before a -17.7% 90-day decline. The current sale occurs when SPRY is trading -19.0% from its 52-week high and down -15.5% over 30 days, near the lower end of its $10.18–$18.35 annual range. Against this backdrop of recent weakness and a documented pattern of selling ahead of subsequent declines at this ticker, the sale warrants attention to whether fundamental deterioration or forward-looking concerns are driving the timing. The company's fundamentals show significant loss ($-44.9M net income on $15.7M revenue) alongside an extreme P/E of 185.88, creating material uncertainty about valuation and path to profitability.

CMO Sarina Tanimoto sells 100,000 SPRY shares at $11.67; stock down 17.9% in 30 days, revenue contracted 97.7% YoY.

Tanimoto sold 100,000 shares (100.0K shares) across 2 separate sales totaling $1,167,100.00 on 2024-12-17 at $11.67 per share, reducing her stake by 8.3%. The timing is notable: SPRY has declined 17.9% over the prior 30 days and 23.4% over 90 days, currently trading at $11.32, down 35.3% from its 52-week high of $17.49. Her prior trades at SPRY show consistent underperformance (30-day declines of 18.8% and 28.4% on recent November sales), with none yet measurable at the 90-day mark. Most concerning are the fundamentals: revenue collapsed 97.7% year-over-year to $2,068,000.00 ($2.1M) in the latest quarter, while the company posted a net loss of $-19,128,000.00 ($-19.1M) for the year. The CMO's sustained selling pattern at a company in financial distress—bleeding cash while revenue has virtually evaporated—coupled with sharp recent stock decline, suggests material operational deterioration rather than routine portfolio management.

CMO Tanimoto Sarina sells 100,000 shares at $13.16–$13.17; stock has fallen 29.8% since transaction, now $12.27

Tanimoto Sarina, Chief Medical Officer, executed 2 separate sales totaling 100,000 shares for $1,316,420.00 on 2024-12-10 at prices of $13.17 and $13.16, reducing her holdings by 8.0% to 1,148,499 shares. The sales occurred amid significant recent price deterioration: the stock is down 29.8% from the 52-week high and down 29.8% over the 30-day period, now trading at $12.27 against the blended average transaction price of $13.16. The sale represents discretionary open-market activity by a key medical executive from an unprofitable, revenue-declined company ($-19.1M net income, -97.7% annual revenue growth), during a period of acute equity pressure. Across all of Tanimoto's open-market history spanning 20 prior sells, her 90-day well-timed rate is 71.43%; however, at this specific ticker (SPRY), the 5 prior sells all remain below 90 days, yielding no measurable outcome pattern yet at this company.

CMO Tanimoto Sarina sells 100,000 shares at $13.95 (totaling $1,394,960.00) as SPRY stock falls -20.3% in 30 days

Tanimoto Sarina, Chief Medical Officer, executed 2 separate sales totaling 100,000 (100.0K shares) for $1,394,960.00 at $13.95 on 2024-11-19, reducing holdings from 1.30M to 1.20M shares (-7.7%). This sale occurs against a backdrop of sharp price deterioration: the stock has declined -20.3% over the prior 30 days and sits -23.5% below its 52-week high of $17.49. The company's fundamentals are under stress—latest quarter revenue was $2.1M with a net loss of $-19.1M, and annual revenue growth contracted -97.7% year-over-year. Notably, this CMO's 5 prior SPRY sales (all in October–November 2024) show no measurable pattern of well-timed selling at the 90-day mark; the most recent prior sale on 2024-10-15 underperformed with a -5.2% 30-day return. The timing of this insider sale amid deteriorating fundamentals and existing price weakness merits investor scrutiny of broader business developments.

CMO Tanimoto Sarina sold 100,000 shares ($1.7M) at $16.85 avg; stock now $14.11 (-19.3% from 52-week high)

On 2024-11-12, Tanimoto Sarina, Chief Medical Officer of ARS Pharmaceuticals (SPRY), executed 4 separate sales totaling 100,000 shares for $1,684,642.45 at prices between $16.76 and $17.64 per share. The sale reduces her holdings by 7.4% to 1,248,499 shares. Stock performance since the transaction is telling: SPRY has fallen from the insider's sale prices by 19.3% from the 52-week high, and is trading at $14.11 today—substantially below all four transaction prices. This transaction occurs against a concerning operational backdrop: the company reported quarterly revenue of $2,068,000.00 with a net loss of $19,128,000.00, and annual revenue has contracted 97.7% year-over-year. Most significantly, her same-ticker history shows 3 consecutive sales on 2024-10-15 (30 days: -5.2%, -7.5%, -5.1%), revealing a pattern of selling into weakness at SPRY over the prior month, all of which have subsequently underperformed or declined.

SPRY CMO Sarina Tanimoto sold 100,000 shares at blended average $14.88 on 2024-10-15 for $1,487,595.07

Tanimoto, Chief Medical Officer of ARS Pharmaceuticals, executed 3 separate sales totaling 100,000 shares for $1,487,595.07, reducing her holdings from 1,398,499 shares to 1,298,499 shares (-7.2%). She continues to hold material stakes at the company. The stock has appreciated 23.6% over the prior 30 days and 53.0% over 90 days, trading at $16.13, only -2.4% from its 52-week high of $16.52. Notably, ARS Pharmaceuticals reported revenue of $500,000.00 in the latest quarter with net income of $-12,516,000.00, and the company faces concerning fundamentals including annual revenue growth of -97.7% year-over-year and continued unprofitability. The timing of a large insider sale amid a steep short-term rally in a high-burn biotech company warrants attention to whether recent price appreciation reflects improving operational prospects or momentum disconnected from fundamentals.

CMO Tanimoto sells 100,000 SPRY shares for $1,382,775 on 2024-10-08; stock +20.8% in 30d before sale

CMO Sarina Tanimoto executed two separate sales totaling 100,000 shares for $1,382,775.00 at $13.83 on 2024-10-08, reducing holdings from 1.45M to 1.35M shares (-6.9%). The sale occurred after a 30-day rally of +20.8% and a 90-day rise of +22.6%, suggesting the insider sold into recent momentum rather than during a decline. The company faces significant fundamentals challenges: annual revenue contracted -97.7% year-over-year to $500.0K in the latest quarter, with a net loss of $-12.5M over the most recent full fiscal year. Tanimoto's cross-ticker track record shows 20 prior sells with a 90-day well-timed rate of 0.00%, indicating this insider's historical sales have not preceded downturns. At SPRY specifically, recent same-ticker sales in late September occurred as the stock was appreciating (+21.0% 30-day return post-trade), though 90-day outcomes remain unmeasurable. The combination of deteriorating fundamentals, strong recent price appreciation, and an insider sale warrant attention given the company's scale-back in revenue and sustained losses.

CMO Tanimoto Sarina sold 100,000 shares (6.7% of holdings) at $12.93 for $1.3M; stock now at $14.86

Tanimoto Sarina, Chief Medical Officer, executed 2 separate sales totaling 100,000 shares for $1,293,205.00 at $12.93 on 2024-09-17, reducing her stake from 1,498,499 shares to 1,398,499 shares. The transaction occurred near the 52-week high ($14.89), with the current price at $14.86 (-0.2% from peak). This represents a meaningful disposal for a C-suite executive at a company with deteriorating fundamentals: ARS Pharmaceuticals reported revenue of $500,000.00 last quarter and a net loss of $-12,516,000.00, with annual revenue contraction of -97.7%. Her cross-ticker track record of 20 prior sells achieved an average 90-day return of +28.0%, but her well-timed rate at 90 days was 0.00%, indicating prior sales preceded gains rather than declines. At this specific ticker, her 5 prior trades (also all sells) show only mixed outcomes on the 30-day horizon (-8.6%, -4.8%, -4.9% on August trades, both September trades still unmeasurable), with no completed 90-day tracking. The scale of the sale, the timing near multi-month highs, and the stark disconnect between the insider's historical execution and the company's operational deterioration warrant monitoring.

CMO Tanimoto Sarina sold 100,000 shares (100.0K shares) for $1.1M on 2024-09-10 at blended average price $11.50.

Tanimoto Sarina, Chief Medical Officer, executed 2 separate sales totaling 100,000 shares for $1,149,775.00 on 2024-09-10, reducing holdings from 1.55M to 1.45M shares (-6.5%). The sale occurred at $11.50, modestly below the current price of $12.63 but near the 30-day performance (-3.3%). Notably, the company reports revenue of $500,000.00 in the latest quarter with net income of $-12.5M, and annual revenue growth of -97.7%, indicating severe operational distress. The insider's cross-ticker track record shows 0.00% well-timed selling rate across 20 prior sales, suggesting his sell timing has historically been consistently poorly-executed relative to subsequent price movements. Recent same-ticker transactions on 2024-08-20 (5 prior sales) lack measurable outcomes, limiting pattern evidence at this specific company.

CMO Sarina Tanimoto sells 100,000 SPRY shares across 6 trades for $1,502,586.53 on 2024-08-20

Tanimoto executed 6 separate sales totaling 100,000 shares (6.3% of her holdings) for $1,502,586.53 at a blended average price of $15.03. This represents a significant liquidation—the transactions took place across multiple price points ($14.76, $15.61, $16.26, $14.76, $15.62, $16.25), consistent with block execution. The timing is notable: these sales occurred after the stock had risen 24.6% in the prior 30 days and 52.3% in the prior 90 days, though the current price of $13.40 sits 10.0% below the 52-week high of $14.89. At SPRY specifically, Tanimoto had executed four additional sales just one week prior (2024-08-13), establishing a pattern of sustained liquidation. The company's financial position is materially challenged: annual revenue growth stands at -97.7%, with quarterly revenue of only $500,000.00 and a net loss of $-12,516,000.00 in the most recent quarter. This deep, recurring sell pattern from a C-level executive at a biotech-stage company experiencing severe financial contraction warrants investor monitoring.